Treatment effect. (A) Primary end point. The red triangle indicates the noninferiority margin. [1] Difference (Diff) (95% CI) was based on estimated difference in percentage with 95% CI. [2] Treatment difference was estimated for eculizumab − ravulizumab. (B) Secondary end point. The red triangle indicates the noninferiority margin. [1] For the end points transfusion avoidance (TA), breakthrough hemolysis (BTH), and stabilized hemoglobin (HGB-S), Diff (95% CI) was based on estimated differences in percentage with 95% CI. For FACIT-Fatigue, Diff (95% CI) was based on estimated difference in change from baseline with 95% CI. [2] Treatment difference was estimated for ravulizumab − eculizumab, except for breakthrough hemolysis, where treatment difference was based on eculizumab − ravulizumab. PCHG, percentage change.